Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, SpainClara Mazagatos, María Isabel Barranco Boada, Olaia Pérez‐Martínez et al.|Influenza and Other Respiratory Viruses|2024Cited by 25
Severity of respiratory syncytial virus compared with SARS-CoV-2 and influenza among hospitalised adults ≥65 yearsLorena Vega-Piris, Susana Monge, José Luis Mayordomo et al.|Journal of Infection|2024Cited by 17
Effectiveness of influenza vaccination during pregnancy to prevent severe infection in children under 6 months of age, Spain, 2017–2019Clara Mazagatos, Pilar Gallego, Pere Godoy et al.|Vaccine|2020Cited by 16
Author response for "Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain"Clara Mazagatos, The SARI Sentinel Surveillance RSV Study Group, Jacobo Mendioroz et al.|Unknown|2024Cited by 0